Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hemoglobin Clear all

Conditions: Hemoglobin SC Disease
Interventions: Hydroxyurea; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 69 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Prediabetic State
Interventions: GlucoSupreme™ Herbal, Placebo; Dietary Supplement · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Anemia of Prematurity
Interventions: Red blood cell transfusion; Procedure
Lead sponsor: McMaster University; Other
Eligibility: Up to 48 Hours
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Albany, New York • Brooklyn, New York

Conditions: Diabetes Mellitus, Type 2, Obesity
Interventions: canagliflozin, Placebo (for canagliflozin); Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 20 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type 2 Diabetes, Hyperglycemia Due to Type 2 Diabetes Mellitus
Interventions: Continuous glucose monitor; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 5 Years to 21 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anemia, Chronic Kidney Disease, Chronic Renal Failure
Interventions: peginesatide; Drug
Lead sponsor: Affymax; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 14
States / cities: Birmingham, Alabama • Pine Bluff, Arkansas • Los Angeles, California + 11 more

Conditions: Hemorrhagic Shock
Interventions: Poly SFH-P Injection; Drug
Lead sponsor: Northfield Laboratories; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 32
States / cities: San Diego, California • Denver, Colorado • Newark, Delaware + 25 more

Conditions: Anemia
Interventions: darbepoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 22
States / cities: Los Angeles, California • Mather, California • Stanford, California + 18 more

Conditions: Type 2 Diabetes Mellitus
Interventions: denagliptin (GW823093); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 57
States / cities: Tallassee, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more

Conditions: Patients Undergoing Spine Surgery
Interventions: intermediate-acting digital nerve block; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sickle Cell Anemia, Hemoglobinopathy, Thalassemia
Interventions: Campath -1H, Dilantin, Busulfan, Cyclophosphamide; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Day to 64 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Diabetes
Interventions: Digital Health Coaching (Patient-Level Intervention), Practice Facilitation (Clinic-Level Intervention); Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hemoglobinopathies, Hemolysis, Iron Deficiency and Overload, Anemias
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Year and older
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hemoglobin SC Disease
Interventions: Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid; Drug · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Oakland, California • Sacramento, California + 14 more

Conditions: Anaemia
Interventions: GSK1278863, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 46
States / cities: Azusa, California • Bakersfield, California • Chino, California + 38 more

Conditions: Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia
Interventions: Fludarabine, Cytarabine, Cellular Infusions, Total Body Irradiation, Cyclophosphamide, Bortezomib, Rituximab, Plasmapheresis; Drug · Device · Radiation + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Hypertension, Hyperlipidemia
Interventions: Pre-filled trays; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type 1, Autoimmune Diseases, Diabetes Mellitus, Endocrine System Diseases, Glucose Metabolism Disorders, Immune System Diseases, Metabolic Diseases
Interventions: Glutamine vs. Placebo, Exercise; Drug · Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 13 Years to 19 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: Pharmacy Managed Diabetes Clinic (PMDC), Standard of Care (SOC); Behavioral · Other
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 75 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Berkley, Michigan • Royal Oak, Michigan • Southfield, Michigan + 1 more

Conditions: HEMOGLOBIN SC DISEASE
Interventions: Mg Pidolate, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Sickle Cell Disease (SCD)
Interventions: Crizanlizumab (SEG101), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Charlotte, North Carolina + 2 more

Conditions: Sickle Red Blood Cell, Fetal Hemoglobin, Oxidative Stress
Interventions: Broccosprouts® (Brassica Protection Products LLC) homogenate; Dietary Supplement
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Renal Impairment
Interventions: GBT021601; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Lake Forest, California • Tustin, California • Miami, Florida + 1 more

Search by objective public record fields.

Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)

RCT of a Polyherbal Dietary Supplement for Prediabetes

Premature Infants in Need of Transfusion (PINT)

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

CGM Use in Children With Type 2 Diabetes

Peginesatide for Anemia in Chronic Hemodialysis Patients

Safety and Efficacy of PolyHeme(R) in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Pre-Hospital Setting

A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)

The Influence of a Bupivacaine Digital Nerve Block Using Rev G.

Hemoglobin Desaturation in Sickle Cell Disease

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Achieving Chronic Care equiTy by leVeraging the Telehealth Ecosystem

Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes

Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease

4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

Treatment of Sickle Cell Anemia With Stem Cell Transplant

Effects of Use of a Connected Pillbox On Medication Adherence

Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes

Impact of Pharmacy Clinic on Diabetes Management

Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

Effect of Broccoli Sprouts Homogenate on SS RBC

Study of GBT021601 in Participants With Renal Impairment